Evaluation of the Cost-Effectiveness of Entecavir Versus Lamivudine in Hepatitis BeAg-Positive Chronic Hepatitis B Patients

BACKGROUND: As new treatment options for chronic hepatitis B virus (HBV) become available, evaluations of cost-effectiveness become important. Entecavir is a deoxyguanine nucleoside analogue approved by the U.S. Food and Drug Administration in March 2005 for HBV infection in adults with evidence of...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Yong, Iloeje, Uchenna H., Hay, Joel, Saab, Sammy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2008
Materias:
Formulary Management
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10438363/
https://www.ncbi.nlm.nih.gov/pubmed/18240879
http://dx.doi.org/10.18553/jmcp.2008.14.1.21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10438363/
https://www.ncbi.nlm.nih.gov/pubmed/18240879
http://dx.doi.org/10.18553/jmcp.2008.14.1.21

Ejemplares similares